Foster City, CA, United States of America

Bainian Feng

This inventor holds 31 USPTO granted patents, plus 3 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Cytokinetics, Inc., Genentech, Inc., Smithkline Beecham Corporation. Active years: 2003-2015.

USPTO Granted Patents = 31

% Patents Active = 48.4

CIPO Patents = 3

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 4.3

ph-index = 14

Forward Citations = 839(Granted Patents)

Location History:

South San Francisco, CA (US) (2012 - 2013)
Foster City, CA (US) (2003 - 2015)

Company Filing History:

Smithkline Beecham Corporation

Seattle Genetics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2003-2015

Loading Chart...

Areas of Expertise:

IAP Inhibitors

Quinazolinones

Heart Failure Treatments

Heterocyclic Linkers

Raf Inhibitors

Self-Immolative Linkers

Pharmaceutical Compounds

Compositions

Methods

KSP Inhibitors

Therapeutic Compositions

Pyrazole Compounds

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8980837 - Inhibitors of IAP (2015-03-17),

2. 8658656 - Methods and compositions utilizing quinazolinones (2014-02-25),

3. 8633236 - Compounds, compositions and methods (2014-01-21),

4. 8470838 - Methods and compositions utilizing quinazolinones (2013-06-25),

5. 8394795 - Pyrazole [3, 4-B] pyridine Raf inhibitors (2013-03-12),

6. 8338452 - Raf inhibitor compounds and methods of use thereof (2012-12-25),

7. 8329928 - Compounds, compositions and methods (2012-12-11),

8. 8119678 - Compounds, compositions and methods (2012-02-21),

9. 8110568 - Inhibitors of IAP (2012-02-07),

10. 8008311 - Methods and compostions utilizing quinazolinones (2011-08-30),

11. 7989434 - Heterocyclic self-immolative linkers and conjugates (2011-08-02),

12. 7919524 - Compounds, compositions and methods (2011-04-05),

13. 7763628 - Methods and compositions utilizing quinazolinones (2010-07-27),

14. 7754681 - Heterocyclic self-immolative linkers and conjugates (2010-07-13),

15. 7671200 - Quinazolinone KSP inhibitors (2010-03-02),

Title: A Closer Look at Innovator Bainian Feng

Introduction: Bainian Feng, based in Foster City, California, is a prolific inventor with an impressive portfolio of 31 patents. His work focuses primarily on the development of novel therapeutic agents aimed at combating serious health conditions, including malignancies and cellular proliferative diseases.

Latest Patents: One of Bainian Feng's notable recent inventions includes compounds that serve as inhibitors of IAP, which are essential for treating malignancies. These compounds follow a specific general formula, demonstrating a sophisticated understanding of chemical interactions in therapeutic applications. Additionally, Feng has disclosed methods and compositions utilizing quinazolinones, which are particularly useful for addressing diseases associated with KSP kinesin activity.

Career Highlights: Feng has made significant contributions in the pharmaceutical industry through his work with well-known companies such as Cytokinetics, Inc. and Genentech, Inc. His expertise in the field has allowed him to explore innovative solutions that bridge the gap between research and application.

Collaborations: Throughout his career, Bainian Feng has collaborated with esteemed professionals, including Gustave Bergnes and Whitney Walter Smith. Together, they have advanced the research and development of groundbreaking therapies, enhancing the medical field's capacity to treat complex diseases.

Conclusion: Bainian Feng's contributions to innovation and invention highlight the crucial role of dedicated inventors in advancing healthcare solutions. With his extensive patent portfolio and collaborations, he continues to drive forward the research that promises better therapeutic interventions for critical health challenges.